C rimean-Congo hemorrhagic fever (CCHF) is a tickborne viral zoonosis. The causative agent, CCHF virus (CCHFV), is a negative-strand RNA virus in the family Nairoviridae. The virus circulates in nature in a vertebrate host-tick cycle, in which the vertebrate hosts are transiently infected and show no overt signs of disease. Ticks are both the vector and the reservoir for CCHFV. Although virus has been detected in a wide range of ticks, not all of these species can transmit or maintain it in nature. Viral epidemiology and experimental studies indicate that ticks of the genus Hyalomma are the main CCHFV vectors and reservoirs. They maintain virus by transmission from one life stage or generation to the next and infect vertebrate hosts, which amplify the virus and infect additional tick populations. CCHFV infection in humans is incidental; exposure occurs through a tick bite, contact with infected blood or tissues, or the crushing of engorged infected ticks. There is a broad spectrum of CCHF disease, from mild flulike illness to bona fide hemorrhagic fever with such hallmark signs as bleeding from puncture sites and orifices, petechial hemorrhage, and diffuse ecchymosis. A brief incubation period of 2 to 7 days is followed by a prehemorrhagic period characterized by fever and a variety of nonspecific signs. In severe cases, patients have elevated levels of liver enzymes and proinflammatory cytokines, prolonged elevation of bleeding markers, and thrombocytopenia, all of which may culminate in either convalescence or death on day 5 to 14 because of shock and multiorgan failure. Cases are typically sporadic, occur in remote or agricultural regions, and are seasonal in association with the life cycle and activity levels of local tick populations. Clusters of disease spread by human-to-human transmission most often occur in nosocomial settings when an infectious cause is not suspected early enough to permit employment of proper barrier precautions.
So why has CCHFV hit Spain now? The virus is widely distributed, having been found from western China, across southern Asia to the Middle East and southeastern Europe, and throughout most of Africa. Although the cases in Spain were unprecedented, they were not unimaginable: evidence of CCHFV circulation was reported more than 6 years ago only 300 km from where exposure of the index case occurred, and Negredo et al. phylogenetically link the virus detected in these recent cases to the virus in the previous report.
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The virus has most likely been in Spain for a while, supported by sufficient populations of two competent tick vectors, Hyalomma marginatum and H. lusitanicum.
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The two species generally do not coexist: H. marginatum prefers open habitats at low elevation, whereas H. lusitanicum is found at higher elevations and in colder areas. The lack of clinical recognition of CCHF in this region predominantly reflects the overall infrequency of human infection; a lack of reported cases in humans in recognized areas of viral presence (infected ticks or serologically positive vertebrate hosts) is not unusual. Either humans are not exposed to hyalomma ticks often enough or the percentage of infected hyalomma ticks is small -or both. Contributors to spillover from enzootic cycles have been identified in previous outbreaks and usually include increases in the population density of vertebrate hosts and ticks to above the maintenance level. At this time, however, the specific ecologic contributors to the recent cases in Spain remain unclear.
Without active surveillance and local access to diagnostic assays (viral RNA detection and serologic tests), the virus could be circulating unnoticed. The absence of reported cases may also reflect lack of recognition of the disease, whether severe or mild. Severe hemorrhagic disease is the most well described clinical presentation of CCHF, but the full spectrum of disease is not known. We are learning that mild or subclinical infections occur more frequently than previously thought. A case in point is Turkey: after CCHF was first recognized there in 2002, Turkey became the first endemic region with consistently high disease incidence, with nearly 10,000 cases reported to date, along with hundreds in neighboring Iran. These cases have had a lower fatality rate -less than 5%, as compared with up to 70% observed in several previous outbreaks.
We do not know when CCHFV was originally introduced into Spain. The viral sequences found there are most closely related to CCHFV strains in northwestern Africa -a finding that supports the theory that the virus was spread northward by migrating birds, rather than entering from the east. General mechanisms of the expansion of CCHFV include transport of ticks by migrating birds and transport of ticks or virus through livestock trade. Another factor influencing gradual changes in tick distribution is climate change, which has contributed to the northward expansion of H. marginatum populations; however, such gradual expansion would not result in the sudden emergence of CCHF in new or distant regions.
The occurrence of CCHF cases outside the historical range of virus circulation highlights the need for enhanced public awareness and education of clinicians both in areas where cases have been reported and where they have yet to occur. Reduced exposure to tick bites and prompt tick removal can help prevent or greatly reduce disease occurrence. In addition, safe practices in other high-risk activities, such as slaughtering of potentially infected livestock, can aid in disease mitigation. Clinicians must recognize that CCHF presents with nonspecific signs that are also seen with several other agents, both hemorrhagic and nonhemorrhagic. A detailed patient history, including occupation, travel, and leisure activities, is important for prioritizing CCHF in the differential diagnosis. Tick bites can go unnoticed, so the lack of reported tick exposure should not cause clinicians to rule out CCHF.
CCHF cases will inevitably occur again in other areas where there is unrecognized viral circulation. As in Spain, these cases will serve as reminders of the largely inconspicuous cycle of CCHFV maintenance in nature. Whereas the natural reservoirs of some other causes of hemorrhagic fever, such as Ebola, have not yet been definitively confirmed, we know how CCHFV is maintained and how virus spillover occurs. When CCHF cases do occur, the transmission potential can be reduced by timely identification of the disease and implementation of barrier-protection and patient-isolation practices. Supportive care remains the mainstay of treatment, and therapeutic intervention requires timely case identification. Although the efficacy of current antiviral options remains debatable, data on ribavirin use promote early administration as more likely to improve patient outcomes. Additional management options, supported by clinical efficacy data, are needed. It is promising that researchers are actively engaged in advanced high-throughput screening of therapeutics and in development of vaccine candidates to aid in these efforts.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
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From the Viral Special Pathogens Branch, F or the year between graduating from college and beginning a doctoral program in clinical psychology, I worked as a researcher in a cardiac surgery department in my hometown of Halifax, Nova Scotia. But on Mondays, Wednesdays, and Fridays, I would leave work in the early afternoon, head down to the hospital lobby, and wait for the shuttle to another part of campus. The 10-minute shuttle ride was my metaphorical and literal transition from hospital employee to patient -though I would keep my hospital badge on, trying to hold tight to the dignity afforded to employees but rarely to patients.
For those 3 days each week, I would sit in the medical day unit (MDU) waiting room -with its pink plastic chairs, outdated magazines, and a television seemingly perpetually broadcasting the Ellen show -until a nurse called me back to take my place in an infusion chair. Then the nurse would dutifully hand me a yellow mask, access my port, and begin infusing the 2 liters of normal saline with added potassium that helped to fend off the chronic dehydration that had set in after my proctocolectomy surgery for Crohn's disease years earlier.
I But for me it was back to the MDU. There, I would spend the infusion time chatting with nurses, asking about their children's soccer tournaments, wheeling my IV pole around to inpatient floors to visit friends who had their own chronic illnesses, but also doing literature searches for work and drafting institutional review board submissions. My days were unevenly split between my identities as researcher and patient, but the patient never disappeared despite the hospital lanyard around my neck, and the researcher never turned off while an IV pump was churning beside me.
Given the hundreds of hours I spent in the MDU, it's not surprising that that was where I found out I was accepted to my firstchoice graduate school. It was also where nurses brought me countless purple popsicles because they knew I loved them, and it would be where I said a tearful goodbye to those nurses before I left for school in the fall.
There were few other patients who earned as many "frequent flyer" miles as I did that year, but some came in each day for a week or once a month for a treatment. The nurses bustled between the infusion rooms lined with their cushioned recliner chairs, checking on patients receiving
